Molecular Pathology and CXCR4 Expression in Surgically Excised Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease

Ophthalmology

Volumn 114, Issue 1, 2007, Pages 147-156

  Liang, Xiaoling ^a   Shen, Defen ^b   Huang, Yongsheng ^a   Yin, Chunyue ^c   Bojanowski, Christine M ^b,d   Zhuang, Zhengping ^c   Chan, Chi Chao ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b NATIONAL EYE INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CASE REPORT; FEMALE; HEMANGIOBLASTOMA; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER COAGULATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETINA TUMOR; RETINAL HEMANGIOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADULT; CHEMOKINES, CXC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MOLECULAR BIOLOGY; RECEPTORS, CXCR4; RETINAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33845729488     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.05.068     Document Type: Article

References (53)

1. Linehan W.M., Lerman M.I., and Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 273 (1995) 564-570
2. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 361 (2003) 2059-2067
3. Richard S., David P., Marsot-Dupuch K., et al. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev 23 (2000) 1-22 discussion 23-4
4. Maher E.R., Webster A.R., and Moore A.T. Clinical features and molecular genetics of Von Hippel-Lindau disease. Ophthalmic Genet 16 (1995) 79-84
5. Welch R.B. Von-Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc 68 (1970) 367-424
6. Singh A.D., Nouri M., Shields C.L., et al. Treatment of retinal capillary hemangioma. Ophthalmology 109 (2002) 1799-1806
7. Aiello L.P., George D.J., Cahill M.T., et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109 (2002) 1745-1751
8. Zbar B., Brauch H., Talmadge C., and Linehan W.M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327 (1987) 721-724
9. Seizinger B.R., Rouleau G.A., Ozelius L.J., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332 (1988) 268-269
10. Kaelin Jr. W.G. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 388 (2005) 627-638
11. Yang H., and Kaelin Jr. W.G. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ 12 (2001) 447-455
12. Yang H., Ivan M., Min J.H., et al. Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. Methods Enzymol 381 (2004) 320-335
13. Hewitson K.S., McNeill L.A., and Schofield C.J. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 10 (2004) 821-833
14. Chan C.C., Vortmeyer A.O., Chew E.Y., et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 117 (1999) 625-630
15. Chan C.C., Lee Y.S., Zhuang Z., et al. von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma. Trans Am Ophthalmol Soc 102 (2004) 75-79 discussion 79-81
16. Chan C.C., Chew E.Y., Shen D., et al. Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis 11 (2005) 697-704
17. Bleul C.C., Farzan M., Choe H., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 (1996) 829-833
18. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
19. Staller P., Sulitkova J., Lisztwan J., et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
20. Zagzag D., Krishnamachary B., Yee H., et al. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65 (2005) 6178-6188
21. Shields J.A., Decker W.L., Sanborn G.E., et al. Presumed acquired retinal hemangiomas. Ophthalmology 90 (1983) 1292-1300
22. Shields J.A., Shields C.L., Honavar S.G., and Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol 131 (2001) 561-571
23. Henkind P., and Morgan G. Peripheral retinal angioma with exudative retinopathy in adults (Coats's lesion). Br J Ophthalmol 50 (1966) 2-11
24. Peyman G.A., Rednam K.R., Mottow-Lippa L., and Flood T. Treatment of large von Hippel tumors by eye wall resection. Ophthalmology 90 (1983) 840-847
25. Schmidt D., Natt E., and Neumann H.P. Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res 5 (2000) 47-58
26. Singh A.D., Shields C.L., and Shields J.A. von Hippel-Lindau disease. Surv Ophthalmol 46 (2001) 117-142
27. Raja D., Benz M.S., Murray T.G., et al. Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease. Visual and anatomic outcomes. Ophthalmology 111 (2004) 150-153
28. Machemer R., and Williams Sr. J.M. Pathogenesis and therapy of traction detachment in various retinal vascular diseases. Am J Ophthalmol 105 (1988) 170-181
29. Obana A., Goto Y., and Ikoma M. A case of von Hippel-Lindau disease with papillary capillary hemangioma treated by photodynamic therapy [in Japanese]. Nippon Ganka Gakkai Zasshi 108 (2004) 226-232
30. Parmar D.N., Mireskandari K., and McHugh D. Transpupillary thermotherapy for retinal capillary hemangioma in von Hippel-Lindau disease. Ophthalmic Surg Lasers 31 (2000) 334-336
31. Girmens J.F., Erginay A., Massin P., et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 136 (2003) 194-196
32. Schmidt D. Retinal angiomatosis [in German]. Klin Monatsbl Augenheilkd 222 (2005) 90-109
33. Laatikainen L., Immonen I., and Summanen P. Peripheral retinal angiomalike lesion and macular pucker. Am J Ophthalmol 108 (1989) 563-566
34. Schwartz P.L., Fastenberg D.M., and Shakin J.L. Management of macular puckers associated with retinal angiomas. Ophthalmic Surg 21 (1990) 550-556
35. McDonald H.R., Schatz H., Johnson R.N., et al. Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment. Ophthalmology 103 (1996) 329-335 discussion 334-5
36. Majji A.B. Paramacular Von Hippel angioma with tractional macular detachment. Ophthalmic Surg Lasers 33 (2002) 145-147
37. Singh A.D., Rundle P.A., and Rennie I. Retinal vascular tumors. Ophthalmol Clin North Am 18 (2005) 167-176 x
38. Kreusel K.M., Bornfeld N., Lommatzsch A., et al. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 105 (1998) 1386-1392
39. Irvine F., O'Donnell N., Kemp E., and Lee W.R. Retinal vasoproliferative tumors: surgical management and histological findings. Arch Ophthalmol 118 (2000) 563-569
40. Rosa Jr. R.H., Goldberg M.F., and Green W.R. Clinicopathologic correlation of argon laser photocoagulation of retinal angiomas in a patient with von Hippel-Lindau disease followed for more than 20 years. Retina 16 (1996) 145-156
41. Shields C.L., Shields J.A., Barrett J., and De Potter P. Vasoproliferative tumors of the ocular fundus: classification and clinical manifestations in 103 patients. Arch Ophthalmol 113 (1995) 615-623
42. Peled A., Petit I., Kollet O., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283 (1999) 845-848
43. Chan C.C., Shen D., Hackett J.J., et al. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology 110 (2003) 421-426
44. Smith J.R., Braziel R.M., Paoletti S., et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101 (2003) 815-821
45. Pugh C.W., and Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 13 (2003) 83-89
46. Claps C.M., Corcoran K.E., Cho K.J., and Rameshwar P. Stromal derived growth factor-1alpha as a beacon for stem cell homing in development and injury. Curr Neurovasc Res 2 (2005) 319-329
47. Kucia M., Ratajczak J., and Ratajczak M.Z. Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells. Biol Cell 97 (2005) 133-146
48. Dalakas E., Newsome P.N., Harrison D.J., and Plevris J.N. Hematopoietic stem cell trafficking in liver injury. FASEB J 19 (2005) 1225-1231
49. Kucia M., Jankowski K., Reca R., et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35 (2004) 233-245
50. Homey B., Muller A., and Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol 2 (2002) 175-184
51. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 (2005) 879-894
52. Greene W.C. The brightening future of HIV therapeutics. Nat Immunol 5 (2004) 867-871
53. Chen Y., Stamatoyannopoulos G., and Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 63 (2003) 4801-4804